エピソード

  • The Menopause Treatment Boom

    The Menopause Treatment Boom
    2026/07/24

    JAMA Medical News Director Jennifer Abbasi and Associate Managing Editor Kate Schweitzer discuss "Wild West or Gold Rush: How Long-Neglected Menopause Care Has Spawned a Booming Marketplace."

    Related Content:

    • Wild West or Gold Rush: How Long-Neglected Menopause Care Has Spawned a Booming Marketplace
    続きを読む 一部表示
    5 分
  • The First CKM Syndrome Guidelines Are Here

    The First CKM Syndrome Guidelines Are Here
    2026/07/17

    JAMA Medical News Director Jennifer Abbasi and Associate Managing Editor Kate Schweitzer discuss "What to Know About the First CKM Syndrome Guidelines."

    Related Content:

    • What to Know About the First CKM Syndrome Guidelines
    続きを読む 一部表示
    5 分
  • The Testosterone Therapy Debate

    The Testosterone Therapy Debate
    2026/07/10

    JAMA Medical News Director Jennifer Abbasi and Associate Managing Editor Kate Schweitzer discuss "Testosterone Therapy: Does New Evidence Warrant Broader Prescribing?"

    Related Content:

    • Testosterone Therapy: Does New Evidence Warrant Broader Prescribing?
    続きを読む 一部表示
    6 分
  • Alzheimer Disease Blood Test May Have Higher Rate of False Positives Than Expected

    Alzheimer Disease Blood Test May Have Higher Rate of False Positives Than Expected
    2026/07/02

    JAMA Medical News Associate Managing Editor Kate Schweitzer and Lead Senior Staff Writer Rita Rubin discuss "First Alzheimer Disease Blood Test May Produce Many False-Positive Results, Study Finds."

    Related Content:

    • First Alzheimer Disease Blood Test May Produce Many False-Positive Results, Study Finds
    続きを読む 一部表示
    6 分
  • PMOS is the New PCOS

    PMOS is the New PCOS
    2026/06/26

    JAMA Medical News Director Jennifer Abbasi and Associate Managing Editor Kate Schweitzer discuss "PCOS is Now PMOS—Will a New Name Translate to Improved Clinical Care?"

    Related Content:

    • PCOS Is Now PMOS—Will a New Name Translate to Improved Clinical Care?
    続きを読む 一部表示
    6 分
  • New GLP-1 Drug Options and More Highlights From the ADA's 2026 Scientific Sessions

    New GLP-1 Drug Options and More Highlights From the ADA's 2026 Scientific Sessions
    2026/06/18

    Rita Kalyani, MD, chief scientific and medical officer at the American Diabetes Association, discusses the latest diabetes and obesity research, including a novel oral GLP-1 drug, a combined semaglutide-amylin analogue injection, data from China on high-dose mazdutide, and more.

    Related Content:

    • A New GLP-1 Pill for Diabetes, Semaglutide With Amylin, Data From China, and More From ADA 2026
    続きを読む 一部表示
    23 分
  • Why Exercise Still Matters in the GLP-1 Drug Era

    Why Exercise Still Matters in the GLP-1 Drug Era
    2026/06/18

    JAMA Medical News Director Jennifer Abbasi and Staff Writer Samantha Anderer discuss "In Obesity Treatment, Physical Activity's Benefits Go Beyond Weight Loss, Says AHA."

    Related Content:

    • In Obesity Treatment, Physical Activity's Benefits Go Beyond Weight Loss, Says AHA
    続きを読む 一部表示
    5 分
  • The Search for a Fentanyl Vaccine

    The Search for a Fentanyl Vaccine
    2026/06/12

    JAMA Medical News Director Jennifer Abbasi and Associate Managing Editor Kate Schweitzer discuss "Inside the Push for a Fentanyl Vaccine."

    Related Content:

    • Inside the Push for a Fentanyl Vaccine
    続きを読む 一部表示
    6 分